Oxycodone for cancer-related pain

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 2, 2015, Pages

  Schmidt Hansen, Mia ^a   Bennett, Michael I ^b   Arnold, Stephanie ^a   Bromham, Nathan ^a   Hilgart, Jennifer S ^a  

^a National Collaborating Centre for Cancer   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MORPHINE; OXYCODONE; DELAYED RELEASE FORMULATION; NARCOTIC ANALGESIC AGENT;

ANALGESIA; CANCER PAIN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INTENTION TO TREAT ANALYSIS; PAIN INTENSITY; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SAMPLE SIZE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; COMPLICATION; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; META ANALYSIS; NEOPLASM; PAIN;

ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; MORPHINE; NEOPLASMS; OXYCODONE; PAIN; PAIN MANAGEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84934325554     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003870.pub5     Document Type: Review

References (81)

1. Beaver WT, Wallenstein SL, Rogers A, Houde RW. Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone. Journal of Pharmacology and Experimental Therapeutics 1978;207(1):92-100.
2. Beaver WT, Wallenstein SL, Rogers A, Houde RW. Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine. Journal of Pharmacology and Experimental Therapeutics 1978;207(1):101-8.
3. Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. Journal of Clinical Oncology 1998;16(10):3222-9.
4. Comerford T, Bruera E. Efficacy of controlled-release oxycodone. Journal of Clinical Oncology 1999;17:738.
5. Gabrail NY, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Current Medical Research and Opinion 2004;20(6):911-8.
6. Gabrail NY, Dvergsten C, Ma T, Frailey A, Ahdieh H. Oxymorphone extended-release (ER) provides safe, effective, and rapid analgesia during opioid radiation: results of a randomized, double-blind, crossover, comparative study with oxycodone controlled-release (CR) [abstract]. Proceedings of the American Society of Clinical Oncology 2003:737.
7. Hagen NA, Babul N. Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain. Cancer 1997;79(7):1428-37.
8. Heiskanen T, Kalso E. Controlled-release oxycodone and morphine in cancer related pain. Pain 1997;73(1):37-45.
9. Heiskanen TE, Ruismaki PM, Seppala TA, Kalso EA. Morphine or oxycodone in cancer pain?. Acta Oncologica 2000;39(8):941-7.
10. Imanaka K, Tominaga Y, Etropolski M, Van Hove I, Ohsaka M, Wanibe M, et al. Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Current Medical Research and Opinion 2013;29:1399-409.
11. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clinical Pharmacology and Therapeutics 1990;47(5):639-46.
12. Kalso E, Vainio A, Mattila MJ, Rosenberg PH, Seppala T. Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays. Pharmacology & Toxicology 1990;67(4):322-8.
13. Kaplan R, Parris WC, Citron ML, Zhukovsky D, Reder RF, Buckley BJ, et al. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. Journal of Clinical Oncology 1998;16(10):3230-7.
14. Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. British Journal of Cancer 2003;89(11):2027-30.
15. Leow KP, Cramond T, Smith MT. Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain. Anesthesia and Analgesia 1995;80(2):296-302.
16. Mercadante S, Tirelli W, David F, Arcara C, Fulfaro F, Casuccio A, et al. Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clinical Journal of Pain 2010;26(9):794-7.
17. Mucci-LoRusso P, Berman BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: A randomized, double-blind, parallel-group study. European Journal of Pain 1998;2(3):239-49.
18. Parris WC, Johnson BW Jr, Croghan MK, Moore MR, Khojasteh A, Reder RF, et al. The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study. Journal of Pain & Symptom Management 1998;16(4):205-11.
19. Riley J, Branford R, Droney J, Gretton S, Sato H, Kennett A, et al. Morphine or oxycodone for cancer-related pain? A randomised, open-label, controlled trial. Journal of Pain and Symptom Management 2014;in press.
20. Riley J, Branford R, Droney J, Gretton S, Sato H, Thick M, et al. A randomised controlled trial of oral morphine versus oral oxycodone for the treatment of pain in cancer patients. Palliative Medicine 2012;26 (4):386.
21. Salzman RT, Roberts MS, Wild J, Fabian C, Reder RF, Goldenheim PD. Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control?. Journal of Pain and Symptom Management 1999;18(4):271-9.
22. Stambaugh JE, Reder RF, Stambaugh M. Double-blind, randomized, two-period crossover efficacy and pharmacokinetic comparison of immediate-release oxycodone (IR) and controlled-release oxycodone (CR) in cancer patients with pain. Clinical Pharmacology and Therapeutics 1997;61(2):197.
23. Stambaugh JE, Reder RF, Stambaugh MD, Stambaugh H, Davis M. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. Journal of Clinical Pharmacology 2001;41(5):500-6.
24. Ahmedzai Sam H, Nauck Friedemann, Bar-Sela Gil, Bosse Bjorn, Leyendecker Petra, Hopp Michael. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliative Medicine 2012;26(1):50-60.
25. Chen HP, Jiang JJ, Li JX. [Efficacy and safety of oxycodone-acetaminophen for moderate and severe visceral pain in advanced cancer patients] LA: Chi. Chinese Journal of New Drugs 2009;18(10):920-2.
26. Dunlop W, Neufeld K. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate to severe pain and opioid-induced constipation despite the use of 2 laxatives: A UK cost utility analysis. Value in Health 2013;16 (7):A384.
27. Garassino MC, Febbraro A, Iorno V, Carbone A, Spagnoletti I, Isa L, et al. Randomized phase ii trial (NCT00637975) evaluating activity and toxicity of fixed dose of oxycodone and increasing dose of pregabalin versus increasing dose of oxycodone and fixed dose of pregabalin for the treatment of oncological neuropathic pain (neuropain-01). Annals of Oncology 2010;21:viii363.
28. Garassino MC, Bianchi A, Febbraro A, Spagnoletti I, Iorno V, Bramati A, et al. Final results of a randomized phase II trial (NCT00637975) evaluating activity and toxicity of fixed-dose oxycodone and increasing dose of pregabalin versus increasing dose of oxycodone and fixed-dose pregabalin for the treatment of oncologic neuropathic pain (NEUROPAIN-01). Journal of Clinical Oncology. Conference: ASCO Annual Meeting 2011;29(15 Suppl 1).
29. Garassino MC, Piva S, Verde N, Spagnoletti I, Iorno V, Carbone C, et al. Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. PloS One 2013, (4):e59981.
30. Leppert W, Ahmedzai SH, Uhl R, Kremers W, Hopp M. Long-term efficacy and safety of the fixed combination oxycodone and naloxone prolonged release (PR) in patients with chronic cancer pain. European Journal of Pain Supplements 2011;5 (1):172.
31. Li RC, He BS. Therapeutic outcome of Tylox for cancer pain in malignant tumor patients with bone metastasis. [Chinese]. Chinese Journal of New Drugs 2008;17(18):1619-21.
32. Li XM, Liu DQ, Wu HY, Yang C, Yang L. Controlled-release oxycodone alone or combined with gabapentin for management of malignant neuropathic pain. Chinese Journal of Cancer Research 2010;22(1):80-6.
33. Meng Xl Tyzj. Effectiveness observation on oxycodone hydrochloride controlled-release tablets for cancer pain. Modern Journal of Integrated Traditional Chinese and Western Medicine [Xian Dai Zhong Xi Yi Jie He Za Zhi] 2008, (2):199-200.
34. Emergency Department (ED) Drug Interaction in Emergency Department Patients. Ongoing Trial 2013.
35. Targin Cancer Pain. Ongoing Trial 2013.
36. Pang J, Jie BJ, Li YP. Efficacy of oxycodone-acetominophen by different administrations in controlling moderate to severe cancer pain and break-out pain. [Chinese]. Chinese Journal of New Drugs 2009;18(18):1767-70, 1776.
37. Shi L, Xiong HH, Yang L, Yu SY. Analgesic effect of oxycodone-acetaminophen tablets in patients with cervical cancer. Chinese Journal of New Drugs 2008;17:1884-5.
38. Sima L, Wu X, Fang W. Oxycodone/acetaminophen combination tablet in patientswith metastatic bone pain: A randomized, double-blinded, placebo-controlled trial. Annals of Oncology 2010;21:378.
39. Sima L, Wu X, Fang W, Li F. Oxycodone/acetaminophen addition to constant opioids in metastatic bone pain: A randomized, double-blinded, controlled, multicenter trial. Journal of Clinical Oncology. Conference 2010;28(15 Suppl 1).
40. Sima L, Fang WX, Wu XM, Li F. Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics 2012;37(1):27-31.
41. Stambaugh JEJ. Analgesic equivalence of Tylox® and Percodan®: Double-blind crossover study of patients with pain from malignancy. Current Therapeutic Research, Clinical and Experimental 1980, (2):302-8.
42. Stambaugh JEJ, Tejada F, Trudnowski RJ. Double-blind comparisons of zomepirac and oxycodone with aspirin phenacetin caffeine in cancer pain. Journal of Clinical Pharmacology 1980;20(4):261-70.
43. Stambaugh JE Jr, Sarajian C. Analgesic efficacy of zomepirac sodium in patients with pain due to cancer. Journal of Clinical Pharmacology 1981;21:501-7.
44. Stambaugh JE, McAdams J. Comparison of the efficacy and safety of oral xorphanol, acetaminophen/oxycodone and placebo in chronic cancer pain. International Journal of Clinical Pharmacology and Therapeutics 1987;41:229.
45. Stambaugh J, Drew J, Johnson J. Comparison of flurbiprofen (Ansaid), oxycodone APAP and placebo in cancer pain, after single and repeat oral doses. Clinical Pharmacology and Therapeutics 1990;47:187.
46. Wu H, Ouyang QC, Liu LP, Wang PH. Safety and efficacy of oxycodone/acetaminophen in treatment of moderate and advanced cancer pain. [Chinese]. Chinese Journal of Cancer Prevention and Treatment 2009;16(18):1432-4.
47. Xiong J, Liang C, Wu X, Zhao YX, Fu L, Zhou YF. Efficacy and safety of oxycodone-acetaminophen tablet in 142 patients with different types of moderate and advanced cancer pain. [Chinese]. Chinese Journal of New Drugs 2008;17(21):1877-9, 1900.
48. Zou J, Wang Q, Liu L. [Efficacy of oxycodone-acetaminophen as an adjuvant of opioid analgesics for cancer pain] LA: Chi. Chinese Journal of New Drugs 2009, (10):923-4.
49. Aurilio C, Sansone P, Pace MC, Passavanti MB, Romano SV, Pota V. Evaluation of efficacy and safety of prolonged-release oxycodone at different dosages for the treatment of severe chronic pain. Pain Practice 2009;9:103.
50. Song JF, Zhao YL, Zhou HM, Wang HJ, Li KY. Efficacies of oxycodone and morphine sulfate sustained-release tablets in treating moderate and severe cancer pain. [Chinese]. Chinese Journal of New Drugs 2009;18(4):337-9.
51. Study to compare the tolerability of slow release oxycodone versus slow release morphine in the treatment of severe cancer pain. The study is geared towards a clinical practice improvement. Ongoing study Not reported.
52. Long term opioid administration in oncologic chronic pain: open label, prospective study on efficacy, safety and pharmacogenetic factors. Ongoing study Not reported.
53. Bukkaalinen fentanyyli syöpäpotilaiden toimenpidekivun hoidossa ("The buccal fentanyl in cancer pain management measure"). Ongoing study Not reported.
54. Randomised, double-blind, cross-over Phase III study to investigate the efficacy and safety of oxycodone after once daily administration of oxycodone HCl XL tablets in comparison to twice daily administration of Oxygesic® tablets in patients with chronic pain. Ongoing study 3 September 2010.
55. Elsayem AF, Bain KT, Palmer JL, Bearden J, Fisch M. A randomized comparison of oral methadone as a "first-switch" opioid versus opioid switching between sustained-release morphine and oxycodone for oncology outpatients with pain management problems. Journal of Clinical Oncology. Conference 2010;28(15 Suppl 1).
56. DS-7113b phase III study A randomized double-blind comparison study with immediate release (IR) oxycodone in opioid-naive patients with cancer pain. 2013.
57. Chronic Administration of Opioids in Cancer Chronic Pain:an Open Prospective Study on Efficacy, Safety and Pharmacogenetic Factors Influence. Ongoing study February 2009.
58. A Randomized, Double-Blind, Active Controlled, Optimal Dose Titration, Multicenter Study to Evaluate the Safety and Efficacy of Oral JNS024 Extended Release (ER) in Japanese and Korean Subjects With Moderate to Severe Chronic Malignant Tumor Related Cancer Pain. Ongoing study August 2012.
59. A Randomized, Double-Blind, Active Controlled, Multi-center Study to Investigate the Safety and Efficacy of OROS Hydromorphone HCl Once-daily Compared With Oxycodone HCL Controlled-release Twice Daily in Subjects With Cancer Pain. Ongoing study December 2009.
60. A Comparative Study of Immediate-Release Oxycodone Capsules Versus Immediate-Release Morphine Tablets for the Treatment of Chinese Patients With Cancer Pain.. Ongoing study December 2010.
61. RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder. Ongoing study April 2011.
62. Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain. Ongoing Trial 2014.
63. Randomized study of fentanyl citrate versus Oxycodone Hydrochloride Hydrate in patients with unresectable advanced pancreatic cancer. 2013.
64. Bekkering GE, Soares-Weiser K, Reid K, Kessels AG, Dahan A, Treede RD, Kleijnen J. Can morphine still be considered to be the standard for treating chronic pain? A systematic review including pair-wise and network meta-analyses. Current Medical Research and Opinion 2011;27:1477-91.
65. Bennett MI. What evidence do we have that the WHO analgesic ladder is effective in cancer pain?. Systematic Reviews in Pain Research; Methodology Refined. McQuay HJ, Moore R, Kalso E (editors). Seattle: IASP Press, 2008:303-13.
66. Breivik H, Cherny N, Collett B, de Conno F, Filbet M, Foubert AJ, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Annals of Oncology 2009;20:1420-33.
67. Caraceni A, Pigni A, Brunelli C. Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project. Palliative Medicine 2011;25:402-9.
68. Caraceni A, Hanks GW, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence based recommendations from the EAPC. Lancet Oncology 2012;13:e58-e68.
69. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Annals of Oncology 2008;19:1985-91.
70. Gudin J. Opioid therapies and Cytochrome P450 interactions. Journal of Pain and Symptom Management 2012;44:S4-S14.
71. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.
72. King SJ, Reid C, Forbes K, Hanks G. S systematic review of oxycodone in the management of cancer pain. Palliative Medicine 2011;25:454-70.
73. Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schünemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;2:81-9.
74. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Available from www.cochrane-handbook.org: The Cochrane Collaboration, 2011.
75. Leppert W. Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacological Report 2010;62:578-91.
76. NICE . Opioids in palliative care CG140. http://www.nice.org.uk/CG140 2012:online.
77. Reid CM, Martin RM, Sterne JAC, Davies AN, Hanks GW. Oxycodone for cancer-related pain: Meta-analysis of randomized controlled trials. Archives of Internal Medicine 2006;166:837-43.
78. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
79. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987;59:851-6.
80. World Health Organization (WHO). Cancer Pain Relief. WHO, Geneva 1986.
81. Reid CM, Davies AN, Hanks GW, Martin RM, Sterne JAC. Oxycodone for cancer-related pain. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD003870.pub3]